Archive | GlycoMimetics

Life Science Leader — Leading Through Adversity: A CEO Roundtable on Drug Development During a Pandemic

lifescileader

Four biopharma CEOs discuss with Rob Wright, chief editor of Life Science Leader, how they are leading their organizations and conducting drug development during the COVID-19 pandemic. Appearing in this video are: Jeremy Levin, DPhil, MB, BChir, CEO of Ovid TherapeuticsGil Van Bokkelen, Ph.D., chairman and CEO of AthersysRachel King, CEO, GlycoMimeticsTed Love, M.D., President […]

Comments Off on Life Science Leader — Leading Through Adversity: A CEO Roundtable on Drug Development During a Pandemic Continue Reading →

BioBuzz: Rachel King of GlycoMimetics Among 12 Women Who Have Shaped the History of the BioHealth Capital Region

Rachel 2018-09-28 Glycomimetics retouch-2-2

The BioHealth Capital Region (BHCR) and its life science ecosystem have a rich and deep history of pioneering scientific innovation, research, development, and commercialization. The region’s history has been written by life science anchor companies, scientific research universities, government research organizations, rich startup culture, and serial entrepreneurs, all of whom have played critical roles in […]

Comments Off on BioBuzz: Rachel King of GlycoMimetics Among 12 Women Who Have Shaped the History of the BioHealth Capital Region Continue Reading →

Washington Business Journal: Maryland Biotech Outlines Path for Blood Cancer Drug, Including in China

logo-glyco

Rockville biotech GlycoMimetics Inc. has entered into a license agreement worth $189 million or more with a West Coast company. The deal gives cancer therapy biopharma Apollomics Inc. of Foster City, California exclusive rights to develop and commercialize GlycoMimetics’ blood cancer drug in greater China, which encompasses mainland China, Hong Kong, Taiwan and Macau, the […]

Comments Off on Washington Business Journal: Maryland Biotech Outlines Path for Blood Cancer Drug, Including in China Continue Reading →

GlycoMimetics CEO Rachel King Featured in Article on Uproleselan

RachelKing

In Cancer, Boosting Chemotherapy while Reducing Toxic Side Effects is a Potential Breakthrough GlycoMimetics is conducting a pivotal Phase 3 trial in the US, Europe and Australia to determine if its drug candidate, uproleselan, can successfully treat patients with relapsed and refractory acute myeloid leukemia (AML), a blood cancer. The unique aspect of uproleselan is […]

Comments Off on GlycoMimetics CEO Rachel King Featured in Article on Uproleselan Continue Reading →

GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel

logo-glyco

ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 29, 2019– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the addition of two senior executives to its executive management team. Eric Feldman, M.D., a specialist in leukemia and bone marrow disorder therapies, has been appointed Vice President of Clinical Development. Christian Dinneen-Long, an attorney with deep experience in the biotechnology industry, has been appointed Vice President and […]

Comments Off on GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel Continue Reading →

GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML

logo-glyco

Evaluating previously untreated newly diagnosed adults with acute myeloid leukemia (AML) who are fit for intensive chemotherapySecond initiation among three late-stage uproleselan clinical trials ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 23, 2019– GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in a Phase 3 clinical trial being conducted under the auspices of a Cooperative Research and Development Agreement […]

Comments Off on GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML Continue Reading →

PressComm PR Client Rachel King, CoFounder and CEO, GlycoMimetics Inc. Featured on PharmaVOICE Podcast

King-Rachel-PVcom-FeaturedImage630x315-560x315

Rachel King has charted a unique career — from consultant to VC to startup to now CEO — and is leading a pioneering company in the use of glycobiology technology. Click here to listen to the podcast via Pharmavoice.com”

Comments Off on PressComm PR Client Rachel King, CoFounder and CEO, GlycoMimetics Inc. Featured on PharmaVOICE Podcast Continue Reading →

GlycoMimetics, Inc. Co-Founder & CEO Rachel K. King Interviewed on New Episode of BHI Podcast – BioTalk with Rich Bendis

MVIMG_20180215_144308 square

Rachel K. King, Co-Founder and CEO, GlycoMimetics, Inc. (GMI), joins Rich Bendis for the latest episode of BioTalk. They cover topics from her background in the industry to running a publicly traded company in the BioHealth Capital Region. Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the […]

Comments Off on GlycoMimetics, Inc. Co-Founder & CEO Rachel K. King Interviewed on New Episode of BHI Podcast – BioTalk with Rich Bendis Continue Reading →